Atypical clinical response patterns to ipilimumab: Four case studies of advanced melanoma

Clinical Journal of Oncology Nursing

Volumn 15, Issue 4, 2011, Pages 393-403

  Ledezma, Blanca ^a   Binder, Sandra ^a   Hamid, Omid ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Angeles Clinic and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER STAGING; CASE REPORT; HUMAN; IMMUNOLOGY; LIVER TUMOR; LUNG TUMOR; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; SPLEEN TUMOR; TREATMENT OUTCOME; VITILIGO;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SPLENIC NEOPLASMS; TREATMENT OUTCOME; VITILIGO;

EID: 79961190854     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.CJON.393-403     Document Type: Article

References (40)

1. Atkins, M.B., Lotze, M.T., Dutcher, J.P., Fisher, R.I., Weiss, G., Margolin, K., Rosenberg, S.A. (1999). High dose recombinant intereluekin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17, 2105-2116.
2. Attia, P., Phan, G.Q., Maker, A.V., Robinson, M.R., Quezado, M.M., Yang, J.C., Rosenberg, S.A. (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology, 23, 6043-6053. doi:10.1200/JCO.2005.06.205
3. Bristol-Meyers Squibb. (2011a). YERVOY™ (ipilimumab) [Prescribing information]. New York, NY: Author.
4. Bristol-Myers Squibb. (2011b). YERVOY™ (ipilimumab) risk evaluation and mitigation strategy. Retrieved from http://www.yervoy.com/hcp/rems.aspx
5. Dougan, M. & Dranoff, G. (2009). Immune therapy for cancer. Annual Review of Immunology, 27, 83-117.
6. Drake, C.G., Jaffee, E., & Pardoll, D.M. (2006). Mechanisms of immune evasion by tumors. Advances in Immunology, 90, 51-81.
7. Dunn, G.P., Old, L.J., & Schreiber, R.D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137-148. doi:10.1016/j.immuni.2004.07.017
8. Eggermont, A.M. (2006). Randomized trials in melanoma: An update. Surgical Oncology Clinics of North America, 15, 439-451.
9. Hamid, O., Urba, W.J., Yellin, M., Nichol, G.M., Weber, J., Hersh, E.M., O'Day, S. (2007). Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma [Abstract 8525]. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings, 25(Suppl. 18), 478s. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8525
10. Hauschild, A. (2009). Adjuvant interferon alfa for melanoma: New evidence-based treatment recommendations? Current Oncology, 16(3), 3-6. doi:10.3747/co.v16i3.447
11. Hauschild, A., Gogas, H., Tarhini, A., Middleton, M.R., Testori, A., Dréno, B., & Kirkwood, J.M. (2008). Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer, 112, 982-994.
12. Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., Dranoff, G. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 105, 3005-3010. doi:10.1073/pnas.0712237105
13. Hodi, F.S., Mihm, M.C., Soiffer, R.J., Haluska, F.G., Butler, M., Seiden, M.V., Dranoff, G. (2003). Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 100, 4712-4717. doi:10.1073/pnas.0830997100
14. Hodi, F.S., O'Day, S., McDermott, D.F., Haanen, J.B., Robert, C., Zhu, X., Wolchok, J.D. (2010). Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma [Abstract 8509]. Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings, 28(Suppl. 15), 613s.
15. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Urba, W.J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711-723. doi:10.1056/NEJMoa1003466
16. Horner, M.J., Ries, L.A.G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., Edwards, B.K. (Eds.). (2009). SEER cancer statistics review, 1975-2006. Retrieved from http://seer.cancer.gov/csr/1975_2006
17. Kim, R., Emi, M., Tanabe, K., & Arihirok, K. (2006). Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Research, 66, 5527-5536.
18. Maker, A.V., Phan, G.Q., Attia, P., Yang, J.C., Sherry, R.M., Topalian, S.L., Rosenberg, S.A. (2005). Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Annals of Surgical Oncology, 12, 1005-1016. doi:10.1245/ASO.2005.03.536
19. Maker, A.V., Yang, J.C., Sherry, R.M., Topalian, S.L., Kammula, U.S., Royal, R.E., Rosenberg, S.A. (2006). Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy, 29, 455-463.
20. Minor, D., Chin, K., & Kashani-Sabet, M. (2009). Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biotherapy and Radiopharmaceuticals, 24, 321-325. doi:10.1089/cbr.2008.0607
21. National Comprehensive Cancer Network. (2010). NCCN Clinical Practice Guidelines in Oncology™: Melanoma [v.1.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
22. O'Day, S.J., Hamid, O., & Urba, W.J. (2007). Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer, 110, 2614-2627.
23. O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., Ibrahim, R. (2010). Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Annals of Oncology, 21, 1712-1717. doi:10.1093/annonc/mdq013
24. Peggs, K.S., Quezada, S.A., Korman, A.J., & Allison, J.P. (2006). Principles and use of anti-CTLA4 antibody in human cancer. Current Opinion in Immunology, 18, 206-213.
25. Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Rosenberg, S.A. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 100, 8372-8377. doi:10.1073/pnas.1533209100
26. Ribas, A., Chmielowski, B., & Glaspy, J.A. (2009). Do we need a different set of response assessment criteria for tumor immunotherapy? Clinical Cancer Research, 15, 7116-7118.
27. Riley, L.B., & Agarwala, S.S. (2008). Melanoma vaccines. Expert Review of Vaccines, 7, 937-949. doi:10.1586/14760584.7.7.937
28. Robert, C., & Ghiringhelli, F. (2009). What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist, 14, 848-861.
29. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Wolchok, J.D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364, 2517-2526.
30. Saenger, Y.M., & Wolchok, J.D. (2008). The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immunity, 8, 1.
31. Schadendorf, D., Algarra, S.M., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A.M., Hersey, P. (2009). Immunotherapy of distant metastatic disease. Annals of Oncology, 20(Suppl. 6), vi41-vi50.
32. Serrone, L., Zeuli, M., Sega, F.M., & Cognetti, F. (2000). Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. Journal of Experimental and Clinical Cancer Research, 19, 21-34.
33. Swann, J.B., & Smyth, M.J. (2007). Immune surveillance of tumors. Journal of Clinical Investigation, 117, 1137-1146. doi:10.1172/JCI31405
34. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Gwyther, S.G. (2000). New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute, 2, 205-216.
35. van Elsas, A., Hurwitz, A.A., & Allison, J.P. (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. Journal of Experimental Medicine, 190, 355-366. doi:10.1084/jem.190.3.355
36. Wankowicz-Kalinska, A., Le Poole, C., van den Wijngaard, R., Storkus, W.J., & Das, P.K. (2003). Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin? Pigment Cell Research, 16, 254-260.
37. Weber, J. (2009). Ipilimumab: Controversies in its development, utility, and autoimmune adverse events. Cancer Immunology, Immunotherapy, 58, 823-830. doi:10.1007/s00262-008-0653-8
38. Weber, J., Thompson, J.A., Hamid, O., Minor, D., Amin, A., Ron, I., O'Day, S.J. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research, 15, 5591-5598. doi:10.1158/1078-0432.CCR-09-1024
39. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C., Hodi, F.S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15, 7412-7420. doi:10.1158/1078-0432.CCR-09-1624
40. Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., O'Day, S.J. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncology, 11, 155-164. doi:10.1016/S1470-2045(09)70334-1